Skip to main content

Discover tailored educational content for your region—select your country to get started

Continue
 

Information, guidance and research on medical cannabis

Curaleaf Education is a platform that aims to provide evidence-based information and improve understanding of medical cannabis.

 

Country-specific education on medical cannabis

Medical cannabis may be considered for symptomatic therapy in a number of conditions. A patient’s treatment pathway is subject to country-level regulation and accessibility. Find out more about access in your area.

1
1

Global leaders in medical cannabis

Specialising in research, development, production and distribution of medical cannabis. Curaleaf International is dedicated to advancing access to cannabis-based medicines through innovative, reliable, evidence-based information.

Discover more about the active compounds within cannabis and the growing body of evidence

Chronic pain
Rheumatic pain
Migraine pain
Oncological pain
Ehlers-Danlos syndrome
Endometriosis, dysmenorrhoea and gynaecological pain

Neuropathic pain
Multiple sclerosis
Epilepsy
Glaucoma
Parkinson’s disease
Autism
Alzheimer’s disease

Chemotherapy-induced nausea and vomiting
Loss of appetite
Cancer-related anxiety and depression

Irritable bowel syndrome
Inflammatory bowel diseases: Crohn’s disease and ulcerative colitis

Anxiety and depression
Insomnia and sleep disorders
Tourette Syndrome
Post-traumatic stress syndrome
Obsessive-compulsive disorder

Psoriasis
Acne

Are you a healthcare professional?

Access our exclusive contents

News

Research

Help from cannabinoids against chemotherapy-induced nausea and vomiting

An Australian study evaluated the efficacy and safety of a THC:CBD extract in the prevention…
Articles

The potential usefulness of endocannabinoids in the treatment of headaches

New treatments are needed to counteract the often debilitating effects of headaches and migraines; the…
Articles

Cannabinoids for chronic pain: when and how to use them

A Canadian working group has conducted a literature review and has drawn up clinical practice…
Articles

Cannabinoids for treatment-resistant epilepsy: what is known

Several studies have assessed the efficacy, safety and tolerability of CBD in addition to drug…

Contact us

    DISCLAIMER

    The information provided on this website is intended solely for educational purposes. The public section contains general information and should not be considered medical advice. Content designated for registered healthcare professionals is restricted to verified individuals in specific jurisdictions and is intended to supplement, not replace, clinical decision-making. Users are advised to consult their local regulations and professional guidelines to ensure compliance.
    By registering to access the information on this site, you confirm that:


    Your personal data will be processed by Curaleaf International Pharma Sagl, Via Trevani, 1, 6600 – Locarno. You may exercise your rights of access, rectification, cancellation, objection, transferability and restriction of the processing of your personal data by sending an email: education@curaleafint.com